Clinical trial

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

NCT02763566

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Abemaciclib Normalized identity: abemaciclibView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Anastrozole Normalized identity: anastrozoleView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Letrozole Normalized identity: letrozoleView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Fulvestrant Normalized identity: fulvestrantView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2016-12-05

PhasePHASE3

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

AbemaciclibDRUG · verified · RxNorm: abemaciclib

AnastrozoleDRUG · verified · RxNorm: anastrozole

LetrozoleDRUG · verified · RxNorm: letrozole

PlaceboDRUG

FulvestrantDRUG · verified · RxNorm: fulvestrant

Sponsors & collaborators

Eli Lilly and Companylead sponsor

Mapped research locations

NanjingJiangsu, China3 WuhanHubei, China3 BeijingBeijing Municipality, China2 ShanghaiShanghai Municipality, China2 GuangzhouGuangdong, China2 HangzhouZhejiang, China2 São PauloBrazil2 ShenyangLiaoning, China2 FuzhouFujian, China2 Porto AlegreRio Grande do Sul, Brazil1 ChangshaHunan, China1 ZhengzhouHenan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02763566 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.